Grifols to market fostamatinib disodium hexahydrate in all potential indications in Europe and Turkey. Rigel Pharma

Rigel Pharmaceuticals, Inc. announced that it has entered into an exclusive license and supply agreement with Spain-based Grifols, S.A to commercialize fostamatinib disodium hexahydrate in all potential indications in Europe and Turkey. Grifols is a global healthcare company and a leading producer of plasma-derived medicines for the treatment of rare and chronic diseases, including intravenous immunoglobulin (IVIG) which is used in the treatment of ITP and AIHA. Fostamatinib is commercially available in the U.S. under the brand name Tavalisse (fostamatinib disodium hexahydrate) and is the first and only SYK inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.